英国晚期与局限性前列腺癌男性的生活质量:一项基于人群的研究
该基于人群的研究通过癌症登记数据调查英国确诊前列腺癌18-42个月的男性,收回35 823份问卷,评估各分期功能结局与健康相关生活质量。结果显示除性功能外各领域功能良好,接受雄激素剥夺治疗者潮热、乏力、体重增加问题更多,性功能障碍普遍且过半男性未获得任何干预。
要点
- 接受雄激素剥夺治疗者潮热(30.7% vs 5.4%)、低能量(29.4% vs 14.7%)、体重增加(22.5% vs 6.9%)报告率高于未接受者。
- 性功能差普遍(81.0%;95% CI 80.6-81.5),与分期无关,55.8%(n=18 782)男性未获得任何干预。
- 晚期与局限性疾病患者报告的健康相关生活质量结局无实质性差异,但激素功能与疲劳问题突出。
核心结论
- 诊断为晚期疾病的男性报告的健康相关生活质量结局与局限性疾病者无实质性差异,但接受雄激素剥夺治疗者报告相当的激素功能与疲劳问题。
- 性功能障碍普遍,多数男性未获得有帮助的干预或支持;需要改善性康复服务并采取措施减少雄激素剥夺治疗的影响。
研究设计与样本
- 基于人群的研究,通过癌症登记数据识别英国确诊前列腺癌后18-42个月的男性。
- 采用邮寄问卷调查,包含EPIC-26简表评估功能结局、EQ-5D-5L评估通用健康相关生活质量及自评健康。
- 使用对数线性与二元逻辑回归模型比较不同诊断分期与自报治疗组间的功能结局与健康相关生活质量,模型校正年龄、社会经济剥夺和 other long-term conditions 数量。
主要发现
- 58 930名男性中35 823名(60.8%)回答了问卷;35 823名中30 733名(85.8%)疾病分期已知,其中19 599名(63.8%)为I或II期,7209名(23.4%)为III期,3925名(12.8%)为IV期。
- 校正后EPIC-26各领域平均分较高提示功能良好,但性功能领域得分低得多。
- 与未接受雄激素剥夺治疗的男性相比,接受该治疗者报告潮热中度至重度问题更多(30.7% [95% CI 29.8-31.6] vs 5.4% [5.0-5.8]),低能量更多(29.4% [95% CI 28.6-30.3] vs 14.7% [14.2-15.3]),体重增加更多(22.5% [21.7-23.3] vs 6.9% [6.5-7.3])。
- 性功能差普遍(81.0%;95% CI 80.6-81.5),与分期无关,超过半数男性(n=18 782 [55.8%])未获得任何帮助该状况的干预。
- 总体自评健康在I-III期疾病男性中相似,IV期癌症者略有降低,但23.5%的转移性疾病男性报告EQ-5D任何维度均无问题。
临床怎么用
- 原文结论指出需要围绕性康复改善服务,并采取措施减少雄激素剥夺治疗的影响。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Little is known about the health-related quality of life (HRQOL) of men living with advanced prostate cancer. We report population-wide functional outcomes and HRQOL in men with all stages of prostate cancer and identify implications for health-care delivery. METHODS: For this population-based study, men in the UK living 18-42 months after diagnosis of prostate cancer were identified through cancer registration data. A postal survey was administered, which contained validated measures to assess functional outcomes (urinary incontinence, urinary irritation and obstruction, bowel, sexual, and vitality and hormonal function), measured with the Expanded Prostate Cancer Index Composite short form (EPIC-26), plus questions about use of interventions for sexual dysfunction) and generic HRQOL (assessed with the 5-level EuroQol five dimensions questionnaire [EQ-5D-5L] measuring mobility, self-care, usual activities, pain or discomfort, and anxiety or depression, plus a rating of self-assessed health). Log-linear and binary logistic regression models were used to compare functional outcomes and HRQOL across diagnostic stages and self-reported treatment groups. Each model included adjustment for age, socioeconomic deprivation, and number of other long-term conditions. FINDINGS: 35 823 (60·8%) of 58 930 men responded to the survey. Disease stage was known for 30 733 (85·8%) of 35 823 men; 19 599 (63·8%) had stage I or II, 7209 (23·4%) stage III, and 3925 (12·8%) stage IV disease. Mean adjusted EPIC-26 domain scores were high, indicating good function, except for sexual function, for which scores were much lower. Compared with men who did not receive androgen deprivation therapy, more men who received the therapy reported moderate to big problems with hot flushes (30·7% [95% CI 29·8-31·6] vs 5·4% [5·0-5·8]), low energy (29·4% [95% CI 28·6-30·3] vs 14·7% [14·2-15·3]), and weight gain (22·5%, 21·7-23·3) vs 6·9% [6·5-7·3]). Poor sexual function was common (81·0%; 95% CI 80·6-81·5), regardless of stage, and more than half of men (n=18 782 [55·8%]) were not offered any intervention to help with this condition. Overall, self-assessed health was similar in men with stage I-III disease, and although slightly reduced in those with stage IV cancer, 23·5% of men with metastatic disease reported no problems on any EQ-5D dimension. INTERPRETATION: Men diagnosed with advanced disease do not report substantially different HRQOL outcomes to those diagnosed with localised disease, although considerable problems with hormonal function and fatigue are reported in men treated with androgen deprivation therapy. Sexual dysfunction is common and most men are not offered helpful intervention or support. Service improvements around sexual rehabilitation and measures to reduce the effects of androgen deprivation therapy are required. FUNDING: The Movember Foundation, in partnership with Prostate Cancer UK.
引用
- Downing A, Wright P, Hounsome L, et al. Quality of life in men living with advanced and localised prostate cancer in the UK: a population-based study. Lancet Oncol. 2019. PMID: 30713036. doi:10.1016/S1470-2045(18)30780-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。